The potential role of lactoferrin and derivatives in the management of infectious and inflammatory complications of hematology patients receiving a hematopoietic stem cell transplantation

Transplant Infectious Disease - Tập 10 Số 2 - Trang 80-89 - 2008
Walter J. F. M. van der Velden1, N.M.A. Blijlevens1, J. Peter Donnelly1
1Department of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Tóm tắt

Abstract: Human lactoferrin is a natural defense protein belonging to the innate immune system present in several body fluids and secretions, as well as in the secondary granules of polymorphonuclear neutrophils. Lactoferrin and its derivatives have pleiotropic functions including broad‐spectrum anti‐microbial activity, anti‐tumor activity, regulation of cell growth and differentiation, and modulation of inflammatory as well as humoral and cellular immune responses. This is the reason why much research has addressed the potential therapeutic activity of these molecules in different clinical settings, especially regarding infectious diseases and uncontrolled inflammatory conditions. In patients with hematological malignancies treated with a hematopoietic stem cell transplantation (HSCT), morbidity and mortality due to infections and uncontrolled inflammation remains high, despite many advances in supportive care. These life‐threatening complications are a result of the damage caused by the conditioning regimens to the mucosal barrier, and the innate and adaptive, humoral, and cellular immune defenses. These complications necessitate the continued exploration of new treatment modalities. Systemic and probably local levels of lactoferrin are decreased following HSCT. Therefore, the use of lactoferrin, or short peptide derivatives that retain the cationic N‐terminal moiety that is essential for the anti‐microbial and anti‐inflammatory activity, may prove to be a promising versatile class of agents for managing the complications that arise from HSCT.

Từ khóa


Tài liệu tham khảo

10.3891/acta.chem.scand.23-0683

10.1084/jem.130.3.643

Broxmeyer HE, 1983, Lactoferrin, transferrin and acidic isoferritins, regulatory molecules with potential therapeutic value in leukemia, 9, 83

10.1111/j.1600-0609.1984.tb02220.x

Bagby GC, 1989, Regulation of granulopoiesis, the lactoferrin controversy, 15, 386

10.1007/BF01963459

10.1016/0009-8981(91)90262-B

10.1038/sj.bmt.1703283

Levy O., 2004, Antimicrobial proteins and peptides, anti-infective molecules of mammalian leukocytes, 76, 909

10.1007/s00018-005-5368-9

Legrand D, 2005, Lactoferrin, a modulator of immune and inflammatory responses, 62, 2549

Gifford JL, 2005, Lactoferricin, a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties, 62, 2588

Suzuki YA, 2005, Mammalian lactoferrin receptors, structure and function, 62, 2560

Valenti P, 2005, Lactoferrin, an important host defence against microbial and viral attack, 62, 2576

Ward PP, 2005, Multifunctional roles of lactoferrin, a critical overview, 62, 2540

10.1073/pnas.94.6.2198

Bennett RM, 1976, A solid‐phase radioimmunoassay for the measurement of lactoferrin in human plasma, variations with age, sex, and disease, 88, 156

10.1139/o06-040

10.1002/1097-4644(20001215)79:4<583::AID-JCB70>3.0.CO;2-9

Van Berkel PH, 1997, N‐terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA, Biochem J, 328, 145, 10.1042/bj3280145

Legrand D, 1997, The N‐terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T‐cells, Biochem J, 327, 841, 10.1042/bj3270841

10.1042/BA20010038

10.1016/S0008-8749(03)00006-6

10.1203/00006450-199608000-00011

10.1128/AAC.44.12.3257-3263.2000

10.1093/jac/dkh346

10.1097/00005176-198901000-00019

10.1139/o06-058

Hanson LA, 1995, Anti‐inflammatory capacities of human milk, lactoferrin and secretory IgA inhibit endotoxin-induced cytokine release, 371, 669

10.1139/o06-039

10.1023/A:1006935908960

10.1203/01.pdr.0000250198.22735.20

10.1046/j.1440-1746.2002.02868.x

Zimecki M, 1996, Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines, Arch Immunol Ther Exp (Warsz), 44, 51

Cumberbatch M, 2003, IL‐1beta‐induced Langerhans' cell migration and TNF‐alpha production in human skin, regulation by lactoferrin, 132, 352

10.1128/CVI.13.2.239-245.2006

10.1111/j.1348-0421.2003.tb02783.x

Teraguchi S, 2004, Protection against infections by oral lactoferrin, evaluation in animal models, 17, 231

10.1007/s00520-002-0407-7

Nagler R, 1996, Major salivary gland dysfunction in human acute and chronic graft‐versus‐host disease (GVHD), Bone Marrow Transplant, 17, 219

Gratwohl A, 2005, Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias, an EBMT analysis of lethal infectious complications and changes over calendar time, 36, 757

10.1038/sj.bmt.1705118

Xun CQ, 1994, Effect of total body irradiation, busulfan‐cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft‐versus‐host disease in H‐2‐incompatible transplanted SCID mice, Blood, 83, 2360, 10.1182/blood.V83.8.2360.2360

Hill GR, 1997, Total body irradiation and acute graft‐versus‐host disease, the role of gastrointestinal damage and inflammatory cytokines, 90, 3204

10.1136/gut.47.5.632

10.1097/01.inf.0000095196.19606.d2

10.1038/sj.bmt.1702517

10.1038/sj.bmt.1703672

Goker H, 2001, Acute graft‐vs‐host disease, pathobiology and management, 29, 259

10.1016/S1083-8791(99)70011-X

10.1172/JCI12156

10.1177/09680519020080061301

10.1056/NEJM198208123070704

10.1099/00222615-48-9-867

10.1172/JCI115407

10.1023/A:1024111310345

10.1128/IAI.69.3.1469-1476.2001

10.1007/BF00189377

10.1128/AAC.46.6.1634-1639.2002

10.1089/scd.2005.14.548

Miyauchi H, 1998, Bovine lactoferrin stimulates the phagocytic activity of human neutrophils, identification of its active domain, 187, 34

10.1128/IAI.70.4.1860-1866.2002

10.1128/IAI.68.12.6519-6525.2000

10.1016/S0014-5793(00)01243-6

10.1128/IAI.66.2.486-491.1998

10.4049/jimmunol.167.5.2921

10.1016/j.femsim.2004.02.006

10.1038/sj.ejcn.1601727

10.1016/S0165-2478(00)00260-1

10.1038/nbt1267

10.1128/AAC.48.12.4919-4921.2004

10.1128/AAC.49.6.2438-2444.2005

Zhang GH, 1999, Neutralization of endotoxin in vitro and in vivo by a human lactoferrin‐derived peptide, Infect Immunol, 67, 1353, 10.1128/IAI.67.3.1353-1358.1999

Lupetti A, 2003, 99mTc‐antimicrobial peptides, promising candidates for infection imaging, 47, 238

10.1016/S0021-9258(19)49900-6

10.1016/S1095-6433(99)00122-1